Insights into Pyrazinamidase and DNA Gyrase Protein Structures in Resistant and Susceptible Clinical Isolates of Mycobacterium tuberculosis.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28210279)

Published in Tanaffos on January 01, 2016

Authors

Azam Ahmadi¹, Raziyeh Nazari², Mohammad Arjomandzadegan³, Mohammad Reza Zolfaghari², Vahideh Vahidi², Toktam Poolad³, Manijeh Kahbazi³, Maryam Sadrnia⁴, Mojtaba Tousheh⁵, Pourya Rafiee³

Author Affiliations

1: Department of Molecular Genetics, Tarbiat Modares University,; Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran.
2: Department of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran.
3: Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran.
4: Department of Biology, Payame Noor University, I.R. of Iran.
5: Department of Cellular and Molecular Medicine, Isfahan University, Isfahan, Iran.

Articles cited by this ↗

Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 2.15

Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob Agents Chemother (2001) 1.76

Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol (2002) 1.52

Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One (2010) 1.35

Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect (2000) 1.32

Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) (2009) 1.29

Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci (2001) 1.27

pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother (2006) 1.21

Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother (2003) 1.17

pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother (2004) 1.17

Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients. J Clin Microbiol (2009) 1.06

Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J Bacteriol (2000) 1.05

Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother (2004) 1.02

Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist (2008) 0.96

Low rates of synonymous mutations in sequences of Mycobacterium tuberculosis GyrA and KatG genes. Tuberculosis (Edinb) (2012) 0.83

Molecular detection of fluoroquinolone resistance-associated gyrA mutations in ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Iran and Belarus. Int J Mycobacteriol (2016) 0.80

Articles by these authors ⇆

Antimycobacterial activity assessment of three ethnobotanical plants against Mycobacterium Tuberculosis: An In Vitro study. Int J Mycobacteriol (2016) 0.77

Minor Contribution of inhA-15 Mutations to the Rapid Detection of Isoniazid Resistance in Mycobacterium Tuberculosis Isolates. Iran J Med Sci (2016) 0.75

Haarlem 3 is the predominant genotype family in multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in the capital of Iran: A 5-year survey. J Glob Antimicrob Resist (2016) 0.75

Isolating and sequencing vB_Kpn_3, a lytic bacteriophage against multidrug-resistant . Future Microbiol (2022) 0.75